Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy

This prospective clinical study aims to evaluate and observe the efficacy and safety of adebrelimab combined with etoposide capsules in maintenance therapy for extensive-stage small cell lung cancer using a single-arm trial design. The study is planned to be conducted in Shaanxi Province, China, with an initial target enrollment of 32 patients. The study commenced in August 2025, and recruitment is expected to conclude around December 2026, with the trial anticipated to end by December 2027. Assuming no occurrences such as withdrawal of informed consent by subjects, intolerable adverse drug r

Trial Details

NCT ID
NCT07141264
Phase
PHASE2
Sponsor
Tang-Du Hospital
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Adebrelimab combined with Etoposide Capsules
Locations (sample)
  • Xi'an, Shannxi, China|34.25833,108.92861

Key Eligibility Criteria

  • Voluntary participation with signed informed consent and good compliance for follow-up.
  • Age between 18 and 75 years old.
  • Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC) according to the AJCC 8th edition or VALG phase II stagi…
  • ECOG performance status score: 0 to 2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →